Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma

BACKGROUND: Despite the progress of advanced target therapeutic agents and immune checkpoint inhibitors, EGFR‐TKI resistance is still one of the biggest obstacles in treating lung cancer. Clinical studies with autophagy inhibitors are actively underway to overcome drug resistance. METHODS: We used P...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Park, Hee Sun, Lee, Da‐Hye, Kang, Da Hyun, Yeo, Min‐Kyung, Bae, Goeun, Lee, Dahye, Yoo, Geon, Kim, Ju‐Ock, Moon, Eunyoung, Huh, Yang Hoon, Lee, Sang‐Hee, Jo, Eun‐Kyeong, Cho, Sang Yeon, Lee, Jeong Eun, Chung, Chaeuk
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2021
Gaiak:
Cancer Biology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7926029/
https://ncbi.nlm.nih.gov/pubmed/33486901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3734
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak